Diabetes mellitus and breast cancer

Lancet Oncology

Volumn 6, Issue 2, 2005, Pages 103-111

  Wolf, Ido ^a   Sadetzki, Siegal ^b,c   Catane, Raphael ^a   Karasik, Avraham ^a   Kaufman, Bella ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIEMETIC AGENT; BIGUANIDE DERIVATIVE; C PEPTIDE; CISPLATIN; ESTRADIOL; ESTROGEN; FLUOROURACIL; GLUCOCORTICOID; GLUCOSE; INSULIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; ORAL ANTIDIABETIC AGENT; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN SHC; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SULFONYLUREA DERIVATIVE; TAXANE DERIVATIVE; TROGLITAZONE; UNINDEXED DRUG; VINCA ALKALOID;

BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG CARCINOGENICITY; DRUG MECHANISM; DRUG MEGADOSE; HIGH RISK POPULATION; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY CANCER; PATHOPHYSIOLOGY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VOMITING;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; HORMONES; HUMANS; INSULIN; SOMATOMEDINS;

EID: 13344270279     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)01736-5     Document Type: Review

References (75)

1. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 27 2004 S5-S10
2. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes Cell 104 2001 517-529
3. The DECODE Study Group Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts Diabetes Care 26 2003 61-69
4. Key TJ Verkasalo PK Banks E. Epidemiology of breast cancer Lancet Oncol 2 2001 133-140
5. van den Brandt PA Spiegelman D Yaun SS et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk Am J Epidemiol 152 2000 514-527
6. Yancik R Wesley MN Ries LA et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older JAMA 285 2001 885-892
7. Czyzyk A Szczepanik Z. Diabetes mellitus and cancer Eur J Intern Med 11 2000 245-252
8. Taha C Klip A. The insulin signaling pathway J Membr Biol 169 1999 1-12
9. Fresno Vara JA Casado E de Castro J et al. PI3K/Akt signalling pathway and cancer Cancer Treat Rev 30 2004 193-204
10. Wolf I Seger R. The mitogen-activated protein kinase signaling cascade: From bench to bedside Isr Med Assoc J 4 2002 641-647
11. Lai A Sarcevic B Prall OW Sutherland RL. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1) J Biol Chem 276 2001 25823-25833
12. Milazzo G Giorgino F Damante G et al. Insulin receptor expression and function in human breast cancer cell lines Cancer Res 52 1992 3924-3930
13. Frittitta L Vigneri R Stampfer MR Goldfine ID. Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a ligand-dependent transformed phenotype J Cell Biochem 57 1995 666-669
14. Papa V Reese CC Brunetti A et al. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells Cancer Res 50 1990 7858-7862
15. Webster NJ Resnik JL Reichart DB et al. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer Cancer Res 56 1996 2781-2788
16. Frittitta L Cerrato A Sacco MG et al. The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice Breast Cancer Res Treat 45 1997 141-147
17. Benson EA Holdaway IM. Regulation of insulin binding to human mammary carcinoma Cancer Res 42 1982 1137-1141
18. Papa V Pezzino V Costantino A et al. Elevated insulin receptor content in human breast cancer J Clin Invest 86 1990 1503-1510
19. Mathieu MC Clark GM Allred DC et al. Insulin receptor expression and clinical outcome in node-negative breast cancer Proc Assoc Am Physicians 109 1997 565-571
20. Goodwin PJ Ennis M Pritchard KI et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study J Clin Oncol 20 2002 42-51
21. Sachdev D Yee D. The IGF system and breast cancer Endocr Relat Cancer 8 2001 197-209
22. Siddle K Urso B Niesler CA et al. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors Biochem Soc Trans 29 2001 513-525
23. Renehan AG Zwahlen M Minder C et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis Lancet 363 2004 1346-1353
24. Friedenreich CM. Review of anthropometric factors and breast cancer risk Eur J Cancer Prev 10 2001 15-32
25. Frystyk J Skjaerbaek C Vestbo E et al. Circulating levels of free insulin-like growth factors in obese subjects: The impact of type 2 diabetes Diabetes Metab Res Rev 15 1999 314-322
26. Nardon E Buda I Stanta G et al. Insulin-like growth factor system gene expression in women with type 2 diabetes and breast cancer J Clin Pathol 56 2003 599-604
27. The Endogenous Hormones and Breast Cancer Collaborative Group Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies J Natl Cancer Inst 94 2002 606-616
28. Nyholm H Djursing H Hagen C et al. Androgens and estrogens in postmenopausal insulin-treated diabetic women J Clin Endocrinol Metab 69 1989 946-949
29. Wideroff L Gridley G Mellemkjaer L et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark J Natl Cancer Inst 89 1997 1360-1365
30. Weiderpass E Gridley G Persson I et al. Risk of endometrial and breast cancer in patients with diabetes mellitus Int J Cancer 71 1997 360-363
31. Michels KB Solomon CG Hu FB et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study Diabetes Care 26 2003 1752-1758
32. Coughlin SS Calle EE Teras LR et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults Am J Epidemiol 159 2004 1160-1167
33. Mink PJ Shahar E Rosamond WD et al. Serum insulin and glucose levels and breast cancer incidence: The atherosclerosis risk in communities study Am J Epidemiol 156 2002 349-352
34. Hjalgrim H Frisch M Ekbom A et al. Cancer and diabetes - a follow-up study of two population-based cohorts of diabetic patients J Intern Med 241 1997 471-475
35. Baron JA Weiderpass E Newcomb PA et al. Metabolic disorders and breast cancer risk (United States) Cancer Causes Control 12 2001 875-880
36. Talamini R Franceschi S Favero A et al. Selected medical conditions and risk of breast cancer Br J Cancer 75 1997 1699-1703
37. La Vecchia C Negri E Franceschi S et al. A case-control study of diabetes mellitus and cancer risk Br J Cancer 70 1994 950-953
38. Weiss HA Brinton LA Potischman NA et al. Breast cancer risk in young women and history of selected medical conditions Int J Epidemiol 28 1999 816-823
39. Bruning PF Bonfrer JM van Noord PA et al. Insulin resistance and breast-cancer risk Int J Cancer 52 1992 511-516
40. Manjer J Kaaks R Riboli E Berglund G. Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: A prospective study within the Malmo Preventive Project Eur J Cancer Prev 10 2001 33-42
41. Lawlor DA Smith GD Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: Findings from the British Women's Heart and Health Study Cancer Causes Control 15 2004 267-275
42. Muti P Quattrin T Grant BJ et al. Fasting glucose is a risk factor for breast cancer: A prospective study Cancer Epidemiol Biomarkers Prev 11 2002 1361-1368
43. Del Giudice ME Fantus IG Ezzat S et al. Insulin and related factors in premenopausal breast cancer risk Breast Cancer Res Treat 47 1998 111-120
44. Jernstrom H Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: The Rancho Bernardo Study J Womens Health Gend Based Med 8 1999 1265-1272
45. Yang G Lu G Jin F et al. Population-based, case-control study of blood C-peptide level and breast cancer risk Cancer Epidemiol Biomarkers Prev 10 2001 1207-1211
46. Ewertz M Holmberg L Tretli S et al. Risk factors for male breast cancer - a case-control study from Scandinavia Acta Oncol 40 2001 467-471
47. Dawson SI. Long-term risk of malignant neoplasm associated with gestational glucose intolerance Cancer 100 2004 149-155
48. Sellers TA Anderson KE Olson JE Folsom AR. Family histories of diabetes mellitus and breast cancer and incidence of postmenopausal breast cancer Epidemiology 9 1998 102-105
49. Zendehdel K Nyren O Ostenson CG et al. Cancer incidence in patients with type 1 diabetes mellitus: A population-based cohort study in Sweden J Natl Cancer Inst 95 2003 1797-1800
50. Sperti C Pasquali C Piccoli A Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas Br J Surg 83 1996 625-631
51. Toyoda H Kumada T Nakano S et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma Cancer 91 2001 957-963
52. Meyerhardt JA Catalano PJ Haller DG et al. Impact of diabetes mellitus on outcomes in patients with colon cancer J Clin Oncol 21 2003 433-440
53. Holmes CE Muss HB. Diagnosis and treatment of breast cancer in the elderly CA Cancer J Clin 53 2003 227-244
54. Bouchardy C Rapiti E Fioretta G et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women J Clin Oncol 21 2003 3580-3587
55. Satariano WA Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer Ann Intern Med 120 1994 104-110
56. Fleming ST Rastogi A Dmitrienko A Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer Med Care 37 1999 601-614
57. Unterburger P Sinop A Noder W et al. Diabetes mellitus and breast cancer. A retrospective follow-up study Onkologie 13 1990 17-20
58. Guastamacchia E Resta F Mangia A et al. Breast cancer: Biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets Curr Drug Targets Immune Endocr Metabol Disord 3 2003 205-209
59. Kath R Schiel R Muller UA Hoffken K. Malignancies in patients with insulin-treated diabetes mellitus J Cancer Res Clin Oncol 126 2000 412-417
60. Anisimov VN Semenchenko AV Yashin AI. Insulin and longevity: antidiabetic biguanides as geroprotectors Biogerontology 4 2003 297-307
61. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers Clin Cancer Res 9 2003 1-9
62. Jiang WG Douglas-Jones A Mansel RE. Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes Int J Cancer 106 2003 752-757
63. Saez E Rosenfeld J Livolsi A et al. PPAR gamma signaling exacerbates mammary gland tumor development Genes Dev 18 2004 528-540
64. Burstein HJ Demetri GD Mueller E et al. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: A phase II study Breast Cancer Res Treat 79 2003 391-397
65. Smith RA Saslow D Sawyer KA et al. American Cancer Society guidelines for breast cancer screening: Update 2003 CA Cancer J Clin 53 2003 141-169
66. Beckman TJ Cuddihy RM Scheitel SM et al. Screening mammogram utilization in women with diabetes Diabetes Care 24 2001 2049-2053
67. Banks E Beral V Cameron R et al. Comparison of various characteristics of women who do and do not attend for breast cancer screening Breast Cancer Res 4 2002 R1
68. Witt A Yavuz D Walchetseder C et al. Preoperative core needle biopsy as an independent risk factor for wound infection after breast surgery Obstet Gynecol 101 2003 745-750
69. Engel J Kerr J Schlesinger-Raab A et al. Quality of life following breast-conserving therapy or mastectomy: Results of a 5-year prospective study Breast J 10 2004 223-231
70. Chon BH Loeffler JS. The effect of nonmalignant systemic disease on tolerance to radiation therapy Oncologist 7 2002 136-143
71. Gogas H Shapiro F Aghajanian C et al. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer Gynecol Oncol 61 1996 22-26
72. Sadoff L. Overwhelming 5-fluorouracil toxicity in patients whose diabetes is poorly controlled Am J Clin Oncol 21 1998 605-607
73. Verstappen CC Heimans JJ Hoekman K Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management Drugs 63 2003 1549-1563
74. Purdie DM Green AC. Epidemiology of endometrial cancer Best Pract Res Clin Obstet Gynaecol 15 2001 341-354
75. Artac M Sari R Altunbas H Karayalcin U. Asymptomatic acute pancreatitis due to tamoxifen-induced severe hypertriglyceridemia in a patient with diabetes mellitus and breast cancer J Chemother 14 2002 309-311